Multiprobe FISH for enhanced detection of bladder cancer in voided urine specimens and bladder washings

American Journal of Clinical Pathology

Volumn 116, Issue 1, 2001, Pages 79-86

  Bubendorf, L ^a   Grilli, B ^a   Sauter, G ^a   Mihatsch, M J ^a   Gasser, T C ^a   Dalquen, P ^a  

^a UNIVERSITY HOSPITAL BASEL   (Switzerland)

Author keywords

Bladder cancer; Bladder washing; FISH; Fluorescence in situ hybridization; Multiprobe; Recurrence; Voided urine

Indexed keywords

ARTICLE; BLADDER CANCER; BLADDER IRRIGATION; CANCER GRADING; CANCER RECURRENCE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CYSTOSCOPY; FLUORESCENCE IN SITU HYBRIDIZATION; HUMAN; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; PROSTATE HYPERTROPHY; SENSITIVITY AND SPECIFICITY; URINALYSIS;

HUMANS; IN SITU HYBRIDIZATION, FLUORESCENCE; IRRIGATION; MALE; PROSPECTIVE STUDIES; PROSTATIC HYPERPLASIA; URINARY BLADDER; URINARY BLADDER NEOPLASMS; URINE;

EID: 0034962559     PISSN: 00029173     EISSN: None     Source Type: Journal    
DOI: 10.1309/K5P2-4Y8B-7L5A-FAA9     Document Type: Article

References (29)

1. Benign papilloma or papillary carcinoma of the bladder?
2. The clinical value of urinary cytology: 12 Years of experience with 615 patients
3. Immunocyt: A new tool for detecting transitional cell cancer of the urinary tract
4. Ancillary methods for the detection of recurrent urothelial neoplasia
5. Marked genetic differences between stage pTa and stage pT1 papillary bladder cancer detected by comparative genomic hybridization
6. Patterns of chromosomal imbalances in advanced urinary bladder cancer detected by comparative genomic hybridization
7. Chromosomal imbalances in noninvasive papillary bladder neoplasms (pTa)
8. Loss of the CDKN2A/p16 locus detected in bladder irrigation specimens by fluorescence in situ hybridization
9. Fluorescence in situ hybridization identifies more aggressive types of primarily noninvasive (stage pTa) bladder cancer
10. DNA aberrations in urinary bladder cancer detected by flow cytometry and FISH
11. A new approach in the diagnosis and follow-up of bladder cancer: FISH analysis of urine, bladder washings, and tumors
12. Cytology, flow cytometry, image analysis, and interphase cytogenetics by fluorescence in situ hybridization in the diagnosis of transitional cell carcinoma in bladder washes: A comparative study
13. Toward the validation of aneusomy detection by fluorescence in situ hybridization in bladder cancer: Comparative analysis with cytology, cytogenetics, and clinical features predicts recurrence and defines clinical testing limitations
14. Chromosome 9 monosomy by fluorescence in situ hybridization of bladder irrigation specimens is predictive of tumor recurrence
15. Chromosomal numerical aberrations detected by fluorescence in situ hybridization on bladder washings from patients with bladder cancer
16. Interphase cytogenetic diagnosis of bladder cancer on cells from urine and bladder washing
17. Chromosomal numerical aberrations of exfoliated cells in the urine detected by fluorescence in situ hybridization: Clinical implication for the detection of bladder cancer
18. The development of a multitarget, multicolor fluorescence in situ hybridization assay for the detection of urothelial carcinoma in urine
19. Chromosomal imbalances are associated with a high risk of progression in early invasive (pT1) urinary bladder cancer
20. A comparison of cytology and fluorescence in situ hybridization for the detection of urothelial carcinoma
21. Urinary level of nuclear matrix protein 22 in the diagnosis of bladder cancer: Experience with 130 patients with biopsy confirmed tumor
22. Tumors of the bladder
23. The accuracy of urinary cytology in daily practice
24. Subclassifying atypical urinary cytology specimens
25. DNA tetraploidy in Feulgen-stained bladder washings assessed by image cytometry
26. The significance of ploidy and proliferation in the clinical and biological evaluation of bladder tumours: A study of 100 untreated cases
27. Frequent genetic alterations in simple urothelial hyperplasias of the bladder in patients with papillary urothelial carcinoma